DRMA
HEALTHCAREDermata Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving DRMA Today?
No stock-specific AI insight has been generated for DRMA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.27
Fundamentals
Trading
DRMA News
18 articles- Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery SystemYahoo Finance·Apr 2, 2026
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025Yahoo Finance·Mar 26, 2026
- Dermata Announces Appointment of Kyra Peckaitis as Vice President, MarketingYahoo Finance·Mar 10, 2026
- Dermata Opens a New Chapter with the Release of Tome SkincareYahoo Finance·Mar 5, 2026
- Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent OfficeYahoo Finance·Jan 20, 2026
- Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 29, 2025
- Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 24, 2025
- A New Realm of Skincare is Coming: Dermata Teases New OTC Brand IdentityYahoo Finance·Dec 4, 2025
- Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent OfficeYahoo Finance·Oct 2, 2025
- Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingYahoo Finance·Sep 18, 2025
- Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025Yahoo Finance·Sep 17, 2025
- Life Science Virtual Investor Forum Agenda Announced for September 18thYahoo Finance·Sep 16, 2025
- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18thYahoo Finance·Sep 16, 2025
- Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care TreatmentsYahoo Finance·Sep 10, 2025
- Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 13, 2025
- Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for HyperhidrosisYahoo Finance·Jul 8, 2025
- Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsYahoo Finance·May 14, 2025
All 18 articles loaded
Price Data
52-Week Range
$1.27
Fundamentals
Trading
About Dermata Therapeutics Inc
Dermata Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative therapies for dermatological conditions. With its lead asset, DMT310, the company employs a novel delivery system designed to enhance treatment efficacy for acne and other skin disorders, thereby addressing significant unmet medical needs within the dermatology market. Dermata's strategically curated pipeline and proprietary technologies highlight its commitment to advancing skin health and improving patient outcomes. As the company progresses through its clinical trials, it is well-positioned to become a leader in the dermatological sector, poised to make a substantial impact on the treatment landscape for skin-related issues.